Adenosine - CAS 58-61-7
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Adenosine
Catalog Number:
58-61-7
CAS Number:
58-61-7
Description:
Adenosine is a purine nucleoside composed of a molecule of adenine attached to a ribose sugar molecule (ribofuranose) moiety via a β-N9-glycosidic bond.
Molecular Weight:
267.24
Molecular Formula:
C10H13N5O4
COA:
Inquire
MSDS:
Inquire
Targets:
Nucleoside Antimetabolite/Analog
Chemical Structure
CAS 58-61-7 Adenosine

Related Nucleoside Antimetabolite/Analog Products


CAS 892128-60-8 LY2334737

LY2334737
(CAS: 892128-60-8)

LY2334737 is an orally available valproic acid ester of gemcitabine, which is a broad-spectrum antimetabolite with antineoplastic activity. It is an orally avai...

CAS 61422-45-5 Carmofur

Carmofur
(CAS: 61422-45-5)

Carmofur or HCFU is a pyrimidine analogue used as an antineoplastic agent. It is a derivative of fluorouracil.

CAS 95058-81-4 Gemcitabine

Gemcitabine
(CAS: 95058-81-4)

Gemcitabine is a nucleoside analog used as chemotherapy.

CAS 154361-50-9 Capecitabine

Capecitabine
(CAS: 154361-50-9)

Capecitabine inhibits tumor growth and metastatic recurrence after resection of human hepatocellular carcinoma (HCC) in highly metastatic nude mice model

CAS 4342-03-4 Dacarbazine

Dacarbazine
(CAS: 4342-03-4)

Dacarbazine is an antineoplastic chemotherapy drug used in the treatment of various cancers.Dacarbazine is a member of the class of alkylating agents, which des...

CAS 183204-72-0 Tipiracil HCl

Tipiracil HCl
(CAS: 183204-72-0)

Tipiralacil, also known as TPI,  is a thymidine phosphorylase inhibitor (TPI). Tipiracil is one of the active components in TAS-102, which is an anticancer...

CAS 122111-03-9 Gemcitabine Hydrochloride

Gemcitabine Hydrochloride
(CAS: 122111-03-9)

Gemcitabine induced NF-κB activity in BxPC-3, PANC-1, and MIA PaCa-2 cells and decreased the level of the NF-κB inhibitor IκBα in BxPC-3 and PANC-1 cells.

CAS 154-42-7 Thioguanine

Thioguanine
(CAS: 154-42-7)

Thioguanine incorporation alters the DNA cleavage induced by topoisomerase II in the presence and absence of etoposide

CAS 121032-29-9 Nelarabine

Nelarabine
(CAS: 121032-29-9)

Nelarabine acts by inhibiting DNA synthesis and inducing apoptosis in susceptible cells. Nelarabine demonstrated significant antineoplastic activity with accept...

CAS 65-86-1 Orotic acid

Orotic acid
(CAS: 65-86-1)

Orotic acid is a heterocyclic compound and an acid. It is manufactured in the body via a mitochondrial enzyme, dihydroorotate dehydrogenase, or a cytoplasmic en...

CAS 147-94-4 Cytarabine

Cytarabine
(CAS: 147-94-4)

Cytarabine (Cytosine arabinoside, AraC) is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.

CAS 69-74-9 Cytarabine hydrochloride

Cytarabine hydrochloride
(CAS: 69-74-9)

Cytarabine, an antimetabolite analogue of cytidine with a modified sugar moiety, is an antimetabolic agent and DNA synthesis inhibitor.

CAS 51-21-8 Fluorouracil

Fluorouracil
(CAS: 51-21-8)

Fluorouracil (5-Fluoracil, 5-FU) is an DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS).

CAS 58-61-7 Adenosine

Adenosine
(CAS: 58-61-7)

Adenosine is a purine nucleoside composed of a molecule of adenine attached to a ribose sugar molecule (ribofuranose) moiety via a β-N9-glycosidic bond.

CAS 65-46-3 Cytidine

Cytidine
(CAS: 65-46-3)

Cytidine is a nucleoside molecule that is formed when cytosine is attached to a ribose ring, cytidine is a component of RNA.

CAS 59-14-3 Bromodeoxyuridine (BrdU)

Bromodeoxyuridine (BrdU)
(CAS: 59-14-3)

Bromodeoxyuridine (BrdU) is a nucleoside analog that competes with thymidine for incorporation into DNA, and used in the detection of proliferating cells.

CAS 123318-82-1 Clofarabine

Clofarabine
(CAS: 123318-82-1)

Clofarabine inhibits the enzymatic activities of ribonucleotide reductase (IC50 = 65 nM) and DNA polymerase.

CAS 75607-67-9 Fludarabine Phosphate

Fludarabine Phosphate
(CAS: 75607-67-9)

Fludarabine Phosphate is an analogue of adenosine and deoxyadenosine, which is able to compete with dATP for incorporation into DNA and inhibit DNA synthesis.

CAS 210829-30-4 Gemcitabine elaidate

Gemcitabine elaidate
(CAS: 210829-30-4)

Gemcitabine elaidate (also known as CO-101; CP-4126) is a lipophilic, unsaturated fatty acid ester derivative of gemcitabine (dFdC), an antimetabolite deoxynucl...

CAS 70-00-8 Trifluridine

Trifluridine
(CAS: 70-00-8)

Trifluorothymidine (TFT) and is an inhibitor of thymidine phosphorylase. TFT also inhibits thymidylate synthase (TS), a rate-limiting enzyme of DNA biosynthesis...

Reference Reading


1.Silicon(IV) phthalocyanines substituted axially with different nucleoside moieties. Effects of nucleoside type on the photosensitizing efficiencies and in vitro photodynamic activities.
Zheng BY1, Shen XM1, Zhao DM1, Cai YB1, Ke MR1, Huang JD2. J Photochem Photobiol B. 2016 Apr 8;159:196-204. doi: 10.1016/j.jphotobiol.2016.03.055. [Epub ahead of print]
A series of new silicon(IV) phthalocyanines (SiPcs) di-substituted axially with different nucleoside moieties have been synthesized and evaluated for their singlet oxygen quantum yields (ΦΔ) and in vitro photodynamic activities. The adenosine-substituted SiPc shows a lower photosensitizing efficiency (ΦΔ=0.35) than the uridine- and cytidine-substituted analogs (ΦΔ=0.42-0.44), while the guanosine-substituted SiPc exhibits a weakest singlet oxygen generation efficiency with a ΦΔ value down to 0.03. On the other hand, replacing axial adenosines with chloro-modified adenosines and purines can result in the increase of photogenerating singlet oxygen efficiencies of SiPcs. The formed SiPcs 1 and 2, which contain monochloro-modified adenosines and dichloro-modified purines respectively, appear as efficient photosensitizers with ΦΔ of 0.42-0.44. Both compounds 1 and 2 present high photocytotoxicities against HepG2 and BGC823 cancer cells with IC50 values ranging from 9nM to 33nM.
2.Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency.
Cicalese MP1, Ferrua F1, Castagnaro L1, Pajno R2, Barzaghi F1, Giannelli S1, Dionisio F1, Brigida I1, Bonopane M1, Casiraghi M1, Tabucchi A3, Carlucci F3, Grunebaum E4, Adeli M5, Bredius RG6, Puck JM7, Stepensky P8, Tezcan I9, Rolfe K10, De Boever E10, Re Blood. 2016 Apr 29. pii: blood-2016-01-688226. [Epub ahead of print]
Adenosine deaminase (ADA) deficiency is a rare, autosomal recessive systemic metabolic disease characterized by severe combined immunodeficiency (SCID). The treatment of choice for ADA-deficient SCID (ADA-SCID) is hematopoietic stem cell transplant (SCT) from a human leukocyte antigen (HLA)-matched sibling donor, although fewer than 25% of patients have such a donor available. Enzyme replacement therapy (ERT) partially and temporarily relieves immunodeficiency. We investigated the medium-term outcome of gene therapy (GT) in 18 patients with ADA-SCID for whom an HLA-identical family donor was not available; most were not responding well to ERT. Patients were treated with an autologous CD34+ enriched cell fraction that contained CD34+ cells transduced with a retroviral vector encoding the human ADA cDNA sequence (GSK2696273) as part of single-arm, open-label studies or compassionate use programs. Overall survival was 100% over 2.3 to 13.4 years (median: 6.
3.Inosine, an Endogenous Purine Nucleoside, Suppresses Immune Responses and Protects Mice from Experimental Autoimmune Encephalomyelitis: a Role for A2A Adenosine Receptor.
Junqueira SC1,2, Dos Santos Coelho I2,3, Lieberknecht V1,2, Cunha MP2,4, Calixto JB5, Rodrigues AL2,4, Santos AR2,3, Dutra RC6,7. Mol Neurobiol. 2016 Apr 30. [Epub ahead of print]
Multiple sclerosis (MS) is a T cell autoimmune, inflammatory, and demyelinating disease of the central nervous system (CNS). Currently available therapies have partially effective actions and numerous side reactions. Inosine, an endogenous purine nucleoside, has immunomodulatory, neuroprotective, and analgesic properties. Herein, we evaluated the effect of inosine on the development and progression of experimental autoimmune encephalomyelitis (EAE), an experimental model of MS. Inosine (1 or 10 mg/kg, i.p.) was administrated twice a day for 40 days. Immunological and inflammatory responses were evaluated by behavioral, histological, immunohistochemical, ELISA, RT-PCR, and Western blotting analysis. The administration of inosine exerted neuroprotective effects against EAE by diminishing clinical signs, including thermal and mechanical hyperalgesia, as well as weight loss typical of the disease. These beneficial effects of inosine seem to be associated with the blockade of inflammatory cell entry into the CNS, especially lymphocytes, thus delaying the demyelinating process and astrocytes activation.
4.The Effect of Endogenous Adenosine on Neuronal Activity in Rats: An FDG PET Study.
Parkinson FE1,2, Paul S1,2, Zhang D3,2, Mzengeza S4, Ko JH3,2. J Neuroimaging. 2016 Apr 15. doi: 10.1111/jon.12349. [Epub ahead of print]
2-18 F-fluorodeoxy-D-glucose (FDG) is a glucose analog that is taken up by cells and phosphorylated. The amount of FDG accumulated by cells is a measure of the rate of glycolysis, which reflects cellular activity. As the levels and actions of the neuromodulator adenosine are dynamically regulated by neuronal activity, this study was designed to test whether endogenous adenosine affects tissue accumulation of FDG as assessed by positron emission tomography (PET) or by postmortem analysis of tissue radioactivity. Rats were given an intraperitoneal injection of the adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropyl-xanthine (DPCPX, 3 mg/kg), the adenosine kinase inhibitor ABT-702 (3 mg/kg), or vehicle 10 minutes prior to an intravenous injection of FDG (15.4 ± 0.7 MBq per rat). Rats were then subjected to a 15 minute static PET scan. Reconstructed images were normalized to FDG PET template for rats and standard uptake values (SUVs) were calculated.